Efficacy of photodynamic therapy with 1/3 dose verteporfin for treating acute central serous chorioretinopathy
Author:
Corresponding Author:

Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    To evaluate the efficacy of photodynamic therapy (PDT) after 1/3 dose verteporfin injection to treat acute central serous chorioretinopathy (CSC). METHODS: Twenty-six eyes of 26 cases diagnosed with acute CSC by fundus fluorescein angiography(FFA) and optical coherence tomography (OCT) examination received one single session of PDT using 1/3 dose (2mg/m2) verteporfin. Best-corrected visual acuity (BCVA) was measured before, 1 week, 4 weeks, and 12 weeks after PDT with 1/3 dose. OCT, FFA and indocyanine green(ICG) examination were performed before, 4 weeks, and 12 weeks after PDT with 1/3 dose. RESULTS:Twenty of 26 eyes (77%) had complete resolution of subretinal fluid (SRF) 1 week after 1/3 dose PDT treatment. After 4 weeks, SRF in 26 eyes was completely absorbed, fluorescein leakage of 22 eyes reduced in FFA and the tortuous choroidal vessels appeared normal in ICG; Twelve weeks after PDT, there was no recurrence of CSC in 26 eyes. The mean BCVA was improved from 0.41 to 0.80 1 week after PDT treatment. CONCLUSION: PDT with 1/3 dose verteporfin injection is effective and safe in treating acute CSC

    Reference
    Related
    Cited by
Get Citation

Dong-Ning Liu, Li Xu, Gui-Jun Gao. Efficacy of photodynamic therapy with 1/3 dose verteporfin for treating acute central serous chorioretinopathy. Guoji Yanke Zazhi( Int Eye Sci) 2012;12(4):708-710

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:February 08,2012
  • Revised:March 07,2012
  • Adopted:
  • Online:
  • Published: